How do biotech B2B sales orgs structure quota for long-cycle clinical-trial deals?

The outcome you should expect

When the architecture is right, four things become observable within two to three quarters of launch. Reps collect a creditable event and a payment in most periods, even though recognized revenue trails their selling effort by years. The company stops paying full commission on awards that never execute, because credit retires only against artifacts a rep cannot manufacture alone — a countersigned work order, an ethics committee approval letter, a documented first-patient-in. Forecast accuracy improves as a side effect, since the same gate data that drives comp also drives the phase-weighted pipeline. And voluntary attrition among tenured enterprise reps falls, because the plan finally pays for the cycle they actually work rather than the cycle a spreadsheet assumes.

Expect friction too, and plan for it. The first two quarters after rollout typically produce disputes over gate definitions, several reps filing tickets about credit timing, and at least one territory where a manager argues the phase map does not match how deals really move. That is normal. What separates orgs that succeed is whether they wrote the gate definitions, the crediting splits, and the hard-case rules down before the plan went live — or whether they are now negotiating them deal by deal, which is how a comp plan loses credibility permanently.

The measurable scoreboard most RevOps teams watch: percentage of reps with at least one creditable event per quarter, median days from gate trigger to credit posting, unrecovered draw balance as a share of quarterly draw, and 24-month retention of reps who sourced at least one award above a defined value threshold. If those four hold steady, the plan is working. If any drifts, the problem is almost always in the weighting or the administration, not in the mechanism itself.

What drives that outcome

The outcome above is not produced by any single mechanism. It emerges from how five interlocking instruments interact across a deal that takes 18 to 48 months to convert a verbal yes into the last dollar of recognized revenue. The diagram below traces the causal chain: what the long cycle breaks, what each mechanism repairs, and where the mechanisms depend on one another.

Three dependencies matter more than the rest. Phase-gated credit is useless without a draw, because a rep who cannot pay rent will not wait for Gate 3. Design-win bonuses are useless without portfolio quotas, because a rep carrying one deal cannot afford to invest a year in early scientific engagement that may never convert. And retention bonuses only work when the underlying plan is stable — a rep will not stay for a year-three bonus if the org rewrites the mechanics every January.

There is a fourth, quieter driver: the phase map itself. Every mechanism above depends on the org maintaining an accurate, shared definition of where each deal actually sits. If the CRM stage data is stale or optimistic, phase-gated credit misfires, the forecast drifts, and the draw reconciliation becomes an argument rather than an arithmetic check. This is why mature biotech RevOps teams treat stage hygiene as a comp input, not a reporting chore.

Benchmarks and realistic ranges

Numbers below are representative ranges for enterprise AEs selling clinical-trial services and software into sponsors. They vary by segment — a CRO selling full-service Phase III awards sits at the top of most ranges; a vendor selling per-study eClinical modules sits lower.

Timing benchmarks matter as much as dollar figures, because they determine how many gates a deal passes inside a single fiscal year.

A representative phase-gate credit schedule for a $4.5M full-service award: 20% retired at verbal award or letter of intent, 30% at executed contract, 25% at study startup with protocol locked and IRB approved, 15% at first patient in, and the final 10% at a mid-execution checkpoint around 50% enrollment or database lock. Weights shift by segment — software vendors front-load contract execution and go-live; CROs weight enrollment heavily because that is where their revenue and risk concentrate.

Adjacent-industry comparables are worth benchmarking against, because biotech is not inventing this from scratch. Capital equipment and aerospace run milestone-based bookings credit with progress payments. Construction uses percentage-of-completion accounting and milestone billing. Government and defense contracting has the richest playbook for crediting team sales across capture managers, proposal teams, and program managers over multi-year awards. A biotech comp designer who studies those three industries will find the structural problem already solved, and can borrow the mechanics rather than re-deriving them.

Risks, edge cases, and failure modes

Every mechanism in this architecture carries its own failure mode, and a sales leader who cannot name them will eventually be surprised by one.

Phase-gated credit creates new surfaces to game. A rep can lean on a sponsor for a soft letter of intent to pull Gate 1 credit forward, or push a thin work order to trip Gate 2 before the study is genuinely funded. The mitigation is that every gate must be tied to an auditable artifact owned by someone other than the rep — a signed work order, an approval letter, a system go-live record. Even then, reps influence timing. Phase-gating reduces gaming versus a pure annual quota; it does not eliminate it.

Recoverable draws can quietly become entitlements. A draw sized to live on is also sized to coast on. Without a hard cumulative unrecovered cap — commonly around two quarters of draw — and a real performance trigger when that cap is breached, the draw stops being an advance and becomes an unfunded salary supplement. The exit treatment also needs to be written down: what happens to outstanding unrecovered draw if the rep leaves, and what happens to unbilled deals they sourced.

Design-win bonuses can reward activity over outcome. Paying $25K–$75K for a protocol design-in is meant to reward a genuinely high-signal leading indicator, but a design-in on a molecule that fails Phase II produces a bonus payment and zero revenue. If the design-win pool grows too large relative to revenue-linked pay, reps optimize for collecting design wins rather than for closing studies that bill. Keep the pool proportionate and tie the largest bonuses to events that only occur after meaningful technical validation.

Portfolio quotas can hide underperformance. A book of five deals diversifies trial-failure risk, but it also blurs accountability. A weak rep can look adequate because two strong installed-base expansion deals carry the number while their new-business origination is dead. The fix is separate new-business and expansion sub-quotas, so the portfolio cannot become a place for underperformance to hide.

Retention bonuses can retain the wrong people. A $100K–$200K year-three bonus keeps reps attached to their deals — including mediocre reps who would otherwise be managed out. Tie retention pay to sourced-deal quality and milestone progress rather than to the calendar alone. A rep whose sourced portfolio is genuinely advancing earns it; a rep coasting on draws while their pipeline stalls does not.

The base-heavy OTE reduces leverage. Running 55–65% base is structurally correct for cash-flow reasons, but it genuinely weakens the plan's ability to drive aggressive behavior. A rep on a rich base through quiet quarters feels less acute pressure to advance deals than a SaaS rep facing a thin draw. Orgs compensate with design-win bonuses and expansion accelerators — that is where the hungry money goes in a base-heavy plan.

The plan assumes a stable deal lifecycle. Decentralized trials, AI-assisted protocol design, platform-subscription pricing, and funding-driven cycle stretching are all reshaping the milestone map. A plan built on 2024's gate definitions can be subtly wrong by 2027 — crediting site activation heavily in a decentralized-trial world where site activation barely exists as a discrete event.

Administrative complexity is itself a risk. A five-mechanism, multi-tranche, portfolio-based, draw-netted plan with hard-case rules is genuinely hard to administer correctly. Every gate is a comp trigger and a forecast input; every CRM stage error is a mispayment. An org that cannot fund the ICM tooling and the RevOps data-hygiene discipline ends up with a sophisticated plan administered badly, which is worse than a simple plan administered well, because reps lose trust in a plan they cannot predict.

Finally, the plan may be over-engineered for shorter-cycle segments. Not every biotech B2B deal is a 40-month full-service trial award. A vendor selling per-study eClinical modules, or reagents and consumables on shorter cycles, may have a 6–12 month cycle that does not need the full apparatus. The most expensive mistake is misclassification in either direction: running an annual SaaS plan on a genuine 40-month cycle produces the gaming-and-churn pathology; bolting the full five-mechanism stack onto a nine-month reagent-resupply business burns RevOps headcount and ICM cost administering risk that does not exist. Measure the genuine median time from verbal yes to the last dollar of recognized revenue on real historical deals, and let that single number classify the plan.

A practical rollout plan

Rolling this out is a two-quarter project, not a January spreadsheet edit. The sequence below is the order that works, because each step produces the data the next step needs.

Step one is measurement, and it is the step most orgs skip. Pull the actual closed deals from the last three years and compute the median span from verbal award to final recognized dollar, per segment. If that span sits inside a single fiscal year, stop — a SaaS-style annual plan is fine. If it stretches past 18 months, the layered plan becomes mandatory rather than optional.

Step two is mapping phase gates to artifacts. For each gate, name the document that proves it happened and the person who owns that document. If no artifact exists, the gate is not creditable.

Step three is credit weighting by segment. A CRO and an eClinical software vendor will not use the same weights, and pretending they will produces a plan that fits neither.

Step four is draw design: amount, recoverability schedule, cumulative cap, and exit treatment. Write the exit treatment before anyone signs, because negotiating it during a departure is when trust breaks.

Step five is quota sizing from capacity, not from a revenue target divided by headcount. How many deals can one AE genuinely manage across all phases? Typically three to six. Multiply by average contract value and the recognition curve, and you have a defensible portfolio number.

Step six is the crediting and split rules for the team sale. A trial award is touched by the enterprise AE, a scientific or medical liaison, a proposal and bid-defense team, sometimes a BDR, and an account manager who inherits during execution. Write the splits down, including the hard cases: reassigned territories, a rep who leaves mid-cycle, a deal sourced by one rep and closed by another after a reorg.

Step seven is the hard-case rules: trial killed after retired gates, trial killed before later gates, sponsor descopes the work order, trial slips a year. The principle is protect retired credit, do not pay for events that never occurred, adjust pro-rata for scope changes, and absorb timing risk through the portfolio.

Step eight is systems. A CRM configured with the real phase stages, an ICM platform configured to retire quota in tranches, net recoverable draws, calculate design-win bonuses, and apply ramp relief, CPQ and contract systems feeding work-order data into the credit engine, and a revenue-recognition model owned jointly by RevOps and finance.

Step nine is the human rollout: a plan handbook with worked examples, a kickoff workshop, and a personalized model showing each rep their territory under the new plan. Reps who can see their own math trust the plan faster than reps who receive a policy document.

Step ten is governance. Freeze the plan annually with a clear effective date, grandfather in-flight deals under the rules they were sourced under, and version every change. Separate the plan, which is frozen, from territory and quota assignments, which can be adjusted at the annual boundary with explicit relief rules. Conflating the two — using a quota reassignment as a backdoor to change comp mechanics on in-flight deals — is the fastest way to lose the trust the whole architecture depends on.

Related questions

How long does it take a new biotech enterprise AE to reach full quota?

Typically 18 to 24 months, stepped roughly 40% in year one, 70% by month 18, and 100% by month 24. The ramp reflects the scientific learning curve, the sponsor relationship build, and the fact that a rep cannot originate and advance a full portfolio inside a sub-cycle window.

Can a rep hit quota without closing a deal in a given year?

Yes. If the plan includes phase-gate credit on in-flight deals and design-win bonuses, a rep can retire meaningful quota and earn real income from milestones on deals awarded in prior years, even when no new award closes inside the fiscal year.

What happens to commission if a trial is cancelled after contract signature?

Credit already retired at the executed-contract gate and earlier is not clawed back. Credit tied to later gates — enrollment, database lock — simply never retires, because those events never occurred. The rep is paid for the deal they genuinely won, not punished for a science outcome they could not control.

How do you credit a deal touched by five people?

Write the split rules before the year starts. The enterprise AE carries primary quota and the bulk of phase-gate commission; scientific liaisons and bid-defense teams typically sit on pooled or MBO-based bonuses tied to win rates; BDRs take a sourcing bonus or a small slice of early-gate credit; account managers take an expansion-revenue split during execution.

Does this architecture work for shorter-cycle biotech segments?

No, and applying it there is a real cost. A vendor selling per-study eClinical modules or reagents on a 6–12 month cycle does not need phase-gated credit, recoverable draws, or portfolio quotas. Measure the actual cycle first; if it fits inside a fiscal year, a simpler annual plan will outperform.

FAQ

What is the single biggest mistake biotech sales orgs make when setting quota?

Applying an annual SaaS bookings quota to an 18-to-48-month cycle. The result is predictable in both directions: reps get paid for unconfirmed paper, or they get paid three years late for work they did in year one — and by then many have left. The fix is decomposing the long cycle into creditable milestones rather than trying to compress it into a single annual number.

Why run a base-heavy pay mix instead of the standard 50/50?

Because a 50/50 split assumes the rep can influence enough closes per year that variable pay is genuinely achievable on a normal cadence. In an 18-to-48-month cycle that assumption fails. Running 55–65% base keeps the rep solvent through the dry quarters and reduces the incentive to game early-stage definitions for survival cash. The trade-off is less leverage, which is why design-win bonuses and expansion accelerators carry the hungry money.

How do you keep reps from coasting on recoverable draws?

Cap cumulative unrecovered draw — commonly around two quarters of draw — and trigger a real performance review when the cap is breached. Reconcile the draw against retired credit every period so both manager and rep see, in dollars, how far ahead or behind actual production sits versus cash taken. That shared number turns the quarterly review into arithmetic rather than a vibe check, and surfaces a struggling rep early.

What should the phase-gate credit weights actually be?

They vary by segment, but a representative full-service CRO schedule is 20% at verbal award, 30% at executed contract, 25% at study startup, 15% at first patient in, and 10% at a mid-execution checkpoint. Software vendors weight contract execution and go-live more heavily. The constant is the principle: quota retires as the deal de-risks, not all at once and not at the very end.

How does this plan interact with forecasting?

Phase-gated credit and honest forecasting need the same data — a phase-accurate, time-phased pipeline where each deal carries a value, a phase, a time-to-next-gate, and a revenue-recognition curve. Aligning comp credit to phase gates forces the org to maintain that data, which is why mature biotech RevOps teams treat stage hygiene as a comp input rather than a reporting chore.

When should the plan be changed?

At the annual boundary, with a clear effective date, and with in-flight deals grandfathered under the rules they were sourced under. A SaaS plan can be retuned every January because the cycle finishes inside the year; a biotech plan touched in June affects deals sourced two years earlier and not closing for two more. Plan stability is a retention input, not a nice-to-have.

Sources

1. WorldatWork — Sales Compensation Programs and Practices — https://worldatwork.org
2. Alexander Group — Sales Compensation and Revenue Growth Advisory — https://www.alexandergroup.com
3. ZS Associates — Pharmaceutical and Life-Sciences Commercial Strategy — https://www.zs.com
4. Korn Ferry — Life Sciences Sales Compensation Benchmarking — https://www.kornferry.com
5. Radford / Aon — Life Sciences Compensation Surveys — https://radford.aon.com
6. CaptivateIQ — Incentive Compensation Management Platform — https://www.captivateiq.com
7. Xactly — Sales Performance and Incentive Compensation Management — https://www.xactlycorp.com
8. Varicent — Incentive Compensation and Sales Planning — https://www.varicent.com
9. IQVIA — Contract Research and Clinical Trial Services — https://www.iqvia.com
10. Medpace — Clinical Research Organization — https://www.medpace.com
11. Veeva Systems — Clinical and Life Sciences Cloud — https://www.veeva.com
12. FASB ASC 606 — Revenue From Contracts With Customers — https://www.fasb.org
13. SEC EDGAR — CRO 10-K Filings — https://www.sec.gov/edgar
14. FDA — Clinical Trial Phases and IRB Documentation — https://www.fda.gov

Related on PULSE

• [How does the 2027 consolidation of analytics tools impact the accuracy of multi-touch attribution in long-cycle deals?](/knowledge/q16317)
• [How should a 2027 CRO benchmark the company against peer GTM orgs for the board?](/knowledge/q12466)
• [How should you structure comp when your GTM model requires both a founder and a sales leader involved in closing — who owns quota, who owns variable pay, and how do you prevent overlap?](/knowledge/q9522)
• [For a founder still running land-and-expand playbooks alongside new enterprise or mid-market motions, how should commission/quota structure differ to prevent cannibalization?](/knowledge/q9526)
• [DevTools sales to engineering orgs: Why do technical evaluations take 4x longer than expected, and how should you compress the proof cycle?](/knowledge/q657)